SCHEMBL2742532

SCHEMBL2742532

COc1ccc(CC2=NCCc3cc(OC)c(OC)cc32)cc1O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 2/20 0.74
KDM4E B2RXH2 5/20 0.63
ALDH1A1 P00352 2/20 0.63
LMNA P02545 1/20 0.63
GLA P06280 1/20 0.57
RCE1 Q9Y256 1/20 0.57
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C19 P33261 1/20 0.55
HSD17B10 Q99714 1/20 0.55
MAOA P21397 4/20 0.51
TDP1 Q9NUW8 1/20 0.50
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
ACHE P22303 1/20 0.48
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2742528 0.90 RAD52 (0.74) RAD52KDM4EALDH1A1LMNAGLA
SCHEMBL29617588 0.90 RAD52 (0.86) RAD52KDM4EALDH1A1LMNAGLA
SCHEMBL2742520 0.90 RAD52 (0.86) RAD52KDM4EALDH1A1LMNAGLA
Hydrochloric Acid SCHEMBL29976040 0.88 RAD52 (0.84) RAD52KDM4EALDH1A1LMNAGLA
Hydrochloric Acid SCHEMBL197624 0.88 RAD52 (0.84) RAD52KDM4EALDH1A1LMNAGLA
SCHEMBL11921690 0.88 KDM4E (0.78) RAD52KDM4EALDH1A1LMNAGLA
SCHEMBL14703886 0.88 RAD52 (0.67) RAD52KDM4EALDH1A1LMNAGLA
SCHEMBL21346178 0.87 RAD52 (0.78) RAD52KDM4EALDH1A1LMNAGLA
SCHEMBL21346110 0.86 RAD52 (0.80) RAD52KDM4EALDH1A1LMNAGLA
Oxalic Acid SCHEMBL32690221 0.85 RAD52 (1.00) RAD52KDM4EALDH1A1LMNAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220387403-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY CVI PHARMACEUTICALS LIMITED (KY) 2022-12-08 US disclosed
US-8815900-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-08-26 US disclosed
US-8815900-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-08-26 US disclosed
US-8710071-B2 Compounds, compositions and methods for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-04-29 US disclosed
US-8710071-B2 Compounds, compositions and methods for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-04-29 US disclosed
US-20120004223-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2012-01-05 US disclosed
US-20120004223-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2012-01-05 US disclosed
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2011-11-03 US disclosed
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2011-11-03 US disclosed
US-8003795-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2011-08-23 US disclosed
US-8003795-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2011-08-23 US disclosed
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2009-02-19 US disclosed
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387403-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY LIPC, FABP1, CPT1A RAD52 4330/4885KDM4E 2429/4885ALDH1A1 299/4885
US-20120004223-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS LIPC, LDLR, PCSK9 RAD52 4180/4885KDM4E 3690/4885ALDH1A1 2335/4885
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS LIPC, LIPE, BCHE RAD52 4768/4885KDM4E 3052/4885ALDH1A1 4477/4885
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS LIPC, BCHE, LIPE RAD52 4788/4885KDM4E 3114/4885ALDH1A1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.